Treating Psoriasis in Older Adults: Balancing Clinical Considerations, Quality of Life, and Access

Managing psoriasis in older adults requires an approach that extends beyond skin disease severity to account for comorbidities, functional limitations, treatment preferences, and access to care. In this episode of Topical Conversations, Harrison Nguyen, MD, and Daniel Butler, MD, discuss the distinct considerations involved in treating psoriasis in an aging population and the importance of individualizing care to meet patients' clinical and practical needs.

Psoriasis in older adults: A broader clinical perspective

Although the clinical features of psoriasis may be similar across age groups, Dr Butler emphasizes that caring for older adults introduces additional complexity. Age-related differences in disease pathophysiology, coexisting medical conditions, and interactions with the health care system can all influence management decisions.

Both experts stress the importance of communicating psoriasis as a systemic inflammatory disease rather than an isolated skin condition. Dr Nguyen notes that moderate to severe psoriasis has been identified as an independent risk factor for cardiovascular events, making assessment of cardiovascular risk particularly relevant in older patients who may already have hypertension, diabetes, or established cardiovascular disease.

Dr Butler encourages dermatologists to consider how psoriasis and its associated inflammation may compound existing health concerns, potentially affecting patients' overall function and quality of life. He describes the skin as a window into the patient's broader health, a perspective he considers especially important in older adults.

Evaluating joint symptoms and overlapping comorbidities

Distinguishing psoriatic arthritis (PsA) from other causes of joint pain can be particularly challenging in older adults, among whom osteoarthritis and other musculoskeletal conditions are common.

Dr Butler explains that joint symptoms in this population are often multifactorial and may not follow classic patterns of inflammatory arthritis. Although morning stiffness that improves with activity can suggest PsA, older patients may present with less characteristic symptoms, overlapping patterns of joint involvement, or stiffness that does not improve as expected. He also highlights the later-onset presentation of psoriasis, noting that disease onset is not limited to younger adulthood.

Dr Nguyen discusses how suspicion of PsA can influence his treatment recommendations. Given the systemic nature of psoriatic disease, potential joint involvement may favor a systemic treatment approach. With biologic and oral therapies available for psoriasis, including agents that also treat PsA, dermatologists have opportunities to address both skin and joint manifestations while collaborating with rheumatology when appropriate.

Individualizing treatment to patient capabilities and priorities

When discussing treatment with older adults, Dr Nguyen emphasizes 2 central goals: minimizing the impact of psoriasis on quality of life and addressing the broader implications of systemic inflammation.

Treatment selection must also account for patients' preferences, daily routines, and ability to administer therapy. Although many biologics are self-injected, some older adults may have arthritis-related dexterity limitations, cognitive impairment, or other challenges that make self-administration difficult.

For these patients, Dr Nguyen may favor a health care professional–administered therapy, which can provide a more structured treatment routine and additional oversight.

Dr Butler reinforces the importance of understanding what matters most to each patient. Symptom relief, functional independence, treatment convenience, and the potential impact of comorbidities may carry different weight depending on individual circumstances. An effective treatment plan must therefore be both clinically appropriate and feasible for the patient to maintain.

Navigating Medicare coverage and treatment access

Beyond clinical considerations, Dr Nguyen and Dr Butler identify medication access and affordability as major factors influencing psoriasis management in older adults.

Dr Butler notes that patients may be unfamiliar with the administrative processes involved in obtaining advanced therapies, including prior authorizations, specialty pharmacy coordination, and potential delays. Clear communication about these steps can help establish realistic expectations and reduce barriers to treatment initiation.

Cost is another important consideration, particularly for patients living on fixed incomes. Although Medicare Part D includes an annual out-of-pocket spending cap for covered prescription drugs, the timing of these expenses can still create financial challenges.

The experts discuss how certain health care professional–administered biologics may be covered under Medicare Part B rather than Part D, offering an alternative coverage pathway for eligible patients. Dr Nguyen emphasizes that understanding the distinctions between Medicare benefits, including the role of supplemental coverage, can help dermatologists identify treatment options that are more accessible for individual patients.

Both experts underscore the importance of clinician advocacy and familiarity with coverage processes. Even a highly effective therapy offers limited benefit if the patient cannot obtain or afford it.

Integrating specialty expertise with whole-patient care

In closing, Dr Nguyen encourages dermatologists to integrate comorbidities, treatment logistics, patient preferences, and access considerations into therapeutic decision-making. The objective is not simply to select an effective medication, but to identify the right treatment for the individual patient at the appropriate time.

Dr Butler echoes this perspective, reminding clinicians that the ability to prescribe a therapy does not necessarily make it the best choice for every patient. Particularly in older adults, thoughtful psoriasis management requires balancing disease control with quality of life, functional capabilities, coexisting conditions, and the realities of treatment delivery.